CN105452458A - 用于治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法 - Google Patents

用于治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法 Download PDF

Info

Publication number
CN105452458A
CN105452458A CN201480044190.5A CN201480044190A CN105452458A CN 105452458 A CN105452458 A CN 105452458A CN 201480044190 A CN201480044190 A CN 201480044190A CN 105452458 A CN105452458 A CN 105452458A
Authority
CN
China
Prior art keywords
ac6mut
cardiac
expression
nucleic acid
cardiomyocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480044190.5A
Other languages
English (en)
Chinese (zh)
Inventor
H·K·哈蒙德
高美华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN105452458A publication Critical patent/CN105452458A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Virology (AREA)
CN201480044190.5A 2013-06-07 2014-06-04 用于治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法 Pending CN105452458A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361832759P 2013-06-07 2013-06-07
US61/832,759 2013-06-07
PCT/US2014/040948 WO2014197624A1 (en) 2013-06-07 2014-06-04 Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

Publications (1)

Publication Number Publication Date
CN105452458A true CN105452458A (zh) 2016-03-30

Family

ID=52008569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480044190.5A Pending CN105452458A (zh) 2013-06-07 2014-06-04 用于治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法

Country Status (14)

Country Link
US (1) US11040091B2 (https=)
EP (1) EP3004343B1 (https=)
JP (1) JP6571069B2 (https=)
KR (1) KR20160032090A (https=)
CN (1) CN105452458A (https=)
AU (1) AU2014274902B2 (https=)
BR (1) BR112015030355A8 (https=)
CA (1) CA2914029A1 (https=)
DK (1) DK3004343T3 (https=)
HK (1) HK1222884A1 (https=)
IL (1) IL242885B (https=)
RU (1) RU2015155831A (https=)
WO (1) WO2014197624A1 (https=)
ZA (1) ZA201508942B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109010799A (zh) * 2018-07-09 2018-12-18 沣潮医药科技（上海）有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
CN109890400A (zh) * 2016-10-24 2019-06-14 光州科学技术院 包含蛋白磷酸酶1抑制肽的血管疾病治疗用组合物
CN111542334A (zh) * 2017-09-29 2020-08-14 贝特基因 用于预防或治疗心律失常的药物组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164920A1 (en) * 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
WO2018090036A1 (en) * 2016-11-14 2018-05-17 Renova Therapeutics, Inc. Method of protection for cardiac tissue
US11760987B2 (en) 2017-09-07 2023-09-19 The Regents Of The University Of California Compositions and methods for the treatment or prevention of heart failure
US20210260215A1 (en) * 2018-06-08 2021-08-26 University Of Florida Research Foundation, Incorporated Aav cardiac gene therapy for cardiomyopathy
CN109191052B (zh) * 2018-10-22 2020-09-25 山东大学 一种多车型车辆路径优化方法、服务器及系统
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395839A1 (en) 1999-12-27 2001-07-05 The Regents Of The University Of California Gene therapy for congestive heart failure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAO ET AL.: "Beneficial effects of adenylyl cyclase type 6 (AC6)expression persist using a catalytically inactive AC6 mutant", 《MOL PHARMACOL.》 *
SUGANO ET AL.: "Activated expression of cardiac adenylyl cyclase 6 reduces dilation and dysfunction fo the pressure-overloaded heart", 《BIOCHEM BIOPHYS RES COMMUN.》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109890400A (zh) * 2016-10-24 2019-06-14 光州科学技术院 包含蛋白磷酸酶1抑制肽的血管疾病治疗用组合物
CN109890400B (zh) * 2016-10-24 2022-12-20 贝特基因公司 包含蛋白磷酸酶1抑制肽的血管疾病治疗用组合物
CN111542334A (zh) * 2017-09-29 2020-08-14 贝特基因 用于预防或治疗心律失常的药物组合物
CN111542334B (zh) * 2017-09-29 2024-01-23 贝特基因 用于预防或治疗心律失常的药物组合物
CN109010799A (zh) * 2018-07-09 2018-12-18 沣潮医药科技（上海）有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
CN109010799B (zh) * 2018-07-09 2021-07-06 沣潮医药科技（上海）有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途

Also Published As

Publication number Publication date
AU2014274902B2 (en) 2020-06-04
IL242885B (en) 2019-12-31
JP2016521708A (ja) 2016-07-25
EP3004343B1 (en) 2018-10-10
CA2914029A1 (en) 2014-12-11
BR112015030355A8 (pt) 2019-12-24
RU2015155831A3 (https=) 2018-03-28
AU2014274902A1 (en) 2015-12-24
JP6571069B2 (ja) 2019-09-04
WO2014197624A1 (en) 2014-12-11
KR20160032090A (ko) 2016-03-23
HK1222884A1 (zh) 2017-07-14
DK3004343T3 (en) 2019-02-04
US11040091B2 (en) 2021-06-22
US20160101164A1 (en) 2016-04-14
ZA201508942B (en) 2019-05-29
BR112015030355A2 (pt) 2017-07-25
EP3004343A1 (en) 2016-04-13
RU2015155831A (ru) 2017-07-14
EP3004343A4 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
CN105452458A (zh) 用于治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法
JP5616016B2 (ja) 生物学的ペースメーカー
CN108310396B (zh) 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
US20160166651A1 (en) Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure
CN116887868A (zh) 达农病的治疗
WO2022011151A1 (en) Mybpc3 polypeptides and uses thereof
US11760987B2 (en) Compositions and methods for the treatment or prevention of heart failure
US20170252462A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
EP3883591B1 (en) Relaxin receptor 1 for use in treatment and prevention of heart failure
WO2015153357A1 (en) Compositions and methods for improving cardiac function

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222884

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160330

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1222884

Country of ref document: HK